TransCelerate BioPharma Inc. Grows, Strengthens Novel Effort to Accelerate Drug Development
TransCelerate BioPharma Inc. ("TransCelerate") today announced that six new pharmaceutical companies have joined as members of the independent non-profit entity formed to assess, refine and create processes to bring innovative new medicines to the public faster. The addition of the new members to TransCelerate marks a major milestone since the organization's founding by ten healthcare and pharmaceutical companies in September 2012. The new member companies include Astellas Pharma Inc., the first member of TransCelerate headquartered in Japan, Biogen Idec, Braeburn Pharmaceuticals, EMD Serono, Inc. (a subsidiary of Merck KGaA, Darmstadt, Germany), Forest Research Institute (a subsidiary of Forest Laboratories, Inc.) and Onyx Pharmaceuticals.
By joining TransCelerate, each of the new companies will contribute financial and other resources, including personnel, to solve industry-wide challenges in a collaborative environment. With these six new members, combined with the ten original founding members, total membership in TransCelerate now stands at 16 companies.
"We are thrilled to expand the membership of TransCelerate BioPharma with these six new companies, we welcome them as members and we look forward to working with them," said Dalvir Gill , PhD, Chief Executive Officer of TransCelerate. "With the addition of these new members, TransCelerate extends its ability to impact global R&D and advance healthcare solutions worldwide."
As initial areas of focus, TransCelerate seeks to provide the following solutions: development of risk-based site monitoring approach and standards, development of a shared user interface for investigator site portals, mutual recognition of study site qualification and training, development of clinical data standards, and establishment of a comparator drug supply model.
"Together, we are leading the effort to develop shared industry solutions to simplify and accelerate the delivery of innovative products to patients – enabled by broad participation and collaboration across the global research and development community," said Dr. Gill.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
